Understanding why neurons and heart cells die prematurely in neurodegenerative and cardiometabolic diseases may hinge on a single molecular tag: a phosphate group added to ubiquitin at one precise amino acid. This biochemical signal sits at the intersection of two of the most consequential cellular processes — mitochondrial quality control and protein waste disposal — making it a compelling target for longevity and disease research alike.
The review, published in the Journal of Biological Chemistry, frames mitochondrial dysfunction not as a downstream consequence of chronic disease but as an active driver within a self-reinforcing pathological loop. Damaged mitochondria produce excess reactive oxygen species, which worsen the misfolding burden on the ubiquitin-proteasome system (UPS), the cell's primary protein disposal mechanism. Critically, the UPS is highly ATP-dependent, meaning it requires healthy mitochondria to function — a circular dependency that, once disrupted, can spiral into the protein aggregation seen in Parkinson's (α-synuclein) and Alzheimer's (tau tangles). Central to the proposed resolution of this cycle is PINK1, a mitochondria-associated kinase that phosphorylates ubiquitin specifically at serine 65 (pSer65-Ub), generating a distress signal that recruits the autophagy machinery for targeted mitochondrial clearance, or mitophagy.
This mechanistic framing carries significant implications. Loss-of-function PINK1 mutations are already established as a cause of early-onset Parkinson's disease, and accumulating evidence links reduced mitophagy flux to normal aging. The pSer65-Ub signal has also attracted interest as a blood-based biomarker for mitochondrial stress, with early clinical data suggesting elevation in neurodegenerative conditions. However, this is a review article rather than a primary clinical trial, and most mechanistic insights remain anchored in cell and animal models. Translating mitophagy enhancement into therapeutic benefit in humans remains an open challenge — small molecules targeting PINK1 or its downstream effector Parkin are in early development but lack Phase II efficacy data. Nonetheless, framing phospho-ubiquitin as a systems-level signal — bridging proteostasis, mitochondrial quality control, and disease — represents a genuinely integrative perspective that moves beyond organ-centric disease models.